BBI Group Acquires DIARECT AG
June 3, 2020
BBI Group has acquired DIARECT AG, a Freiburg-based supplier of recombinant autoimmune antigen products, integrating DIARECT's manufacturing facility to establish a centre of excellence for recombinant antigen development. The deal expands BBI's immunoassay reagent portfolio and capabilities, enabling the combined company to pursue high-growth disease segments and broaden DIARECT's geographic reach through BBI's larger sales organization.
- Buyers
- BBI Group
- Targets
- DIARECT AG
- Industry
- Medical Devices
- Location
- Baden-Württemberg, Germany
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Anteo Diagnostics Acquires DIAsource ImmunoAssays SA
August 26, 2015
Medical Devices
Anteo Diagnostics will acquire 100% of DIAsource ImmunoAssays SA for EUR15.4m (with a two-year vendor earn-out), expanding Anteo's product range, manufacturing capabilities and global distribution. DIAsource, headquartered in Louvain-la-Neuve, Belgium, reported EUR11.9m revenue in 2014 (EUR7.2m in H1 2015) and the combined business will total about 100 personnel; the deal is subject to financing and regulatory approvals.
-
BBI Solutions Acquires IBEX Technologies Inc.
April 8, 2024
Biotechnology
BBI Solutions OEM Limited has acquired IBEX Technologies Inc., a Montreal-based developer and manufacturer of high-precision enzymes and diagnostic solutions, with the transaction closing on April 8, 2024. The acquisition expands BBI's recombinant protein and enzyme capabilities to better serve in-vitro diagnostics (IVD) manufacturers and brings IBEX's staff and contract-manufacturing capabilities into BBI's global operations.
-
BioCheck, Inc. Acquires DRG International, Inc.
August 18, 2021
Medical Devices
BioCheck, Inc. has acquired DRG International, Inc., a manufacturer of clinical diagnostic ELISAs and the DRG:HYBRiD-XL automated analyzer. The deal combines BioCheck's chemiluminescent assay development and automation platform with DRG's R&D, manufacturing and global distribution network to accelerate development and global scale-up of advanced clinical and research diagnostic tests.
-
Agilent Technologies to Acquire Biocare Medical for $950 Million
March 9, 2026
Healthcare Services
Agilent Technologies entered into a definitive agreement to acquire Biocare Medical, a global provider of clinical and research pathology solutions, in an all-cash transaction valued at $950 million. The deal is designed to expand Agilent’s pathology portfolio—especially immunohistochemistry—and is expected to close no later than Agilent’s fourth fiscal quarter of 2026.
-
R-Biopharm AG Acquires AusDiagnostics
June 7, 2022
Biotechnology
German biotechnology company R-Biopharm AG has acquired Australian molecular diagnostics manufacturer AusDiagnostics. The purchase adds AusDiagnostics' multiplex MT-PCR platforms, extraction reagents and laboratory automation capabilities to R-Biopharm's clinical diagnostics portfolio, supporting capability expansion and internationalization into new clinical, veterinary and applied testing markets.
-
Novo Holdings Acquires BBI Group
June 15, 2021
Medical Devices
Novo Holdings A/S has agreed to acquire BBI Group from Exponent for an enterprise value of over GBP 400 million, becoming the company's majority shareholder. BBI, a Crumlin, South Wales–headquartered supplier of diagnostics reagents, lateral flow development and diagnostic manufacturing services with more than 400 employees, will benefit from Novo Holdings' life-sciences expertise to pursue organic and inorganic growth.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.